Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.29 CHF | +3.30% | -3.66% | -4.36% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.36% | 115M | C | ||
-3.19% | 102B | B+ | ||
+1.73% | 96.29B | B+ | ||
+2.13% | 22.18B | B | ||
-15.71% | 21.2B | B+ | ||
-9.21% | 18.31B | A- | ||
-39.98% | 17.38B | A- | ||
-15.86% | 16.36B | B | ||
+4.96% | 13.97B | C+ | ||
+31.96% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MOLN Stock
- Ratings Molecular Partners AG